We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Relay Therapeutics, Inc. (RLAY - Free Report) shares ended the last trading session 16.4% higher at $12.54. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.1% gain over the past four weeks.
Relay Therapeutics’ share price gain reflects growing investor confidence in the strength of its lead asset, zovegalisib (RLY-2608), a PI3Kα inhibitor, which is advancing into late-stage development with an ongoing phase III breast cancer study (ReDiscover-2). The drug is also being expanded into earlier-line breast cancer settings and non-oncology indications like vascular malformations, with multiple data readouts expected in 2026. The company is also advancing RLY-8161 for Fabry disease, strengthening its genetic disease pipeline. Meanwhile, its FGFR2 inhibitor lirafugratinib (RLY-4008) has been out-licensed to Elevar and already has an NDA filed with the FDA.
This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +23.9%. Revenues are expected to be $15.35 million, up 99.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Relay Therapeutics, the consensus EPS estimate for the quarter has been revised 4.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on RLAY going forward to see if this recent jump can turn into more strength down the road.
Relay Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, electroCore, Inc. (ECOR - Free Report) , closed the last trading session 3% higher at $6.8. Over the past month, ECOR has returned -17.2%.
electroCore's consensus EPS estimate for the upcoming report has changed -10.1% over the past month to -$0.59. Compared to the company's year-ago EPS, this represents a change of -25.5%. electroCore currently boasts a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
Relay Therapeutics, Inc. (RLAY - Free Report) shares ended the last trading session 16.4% higher at $12.54. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.1% gain over the past four weeks.
Relay Therapeutics’ share price gain reflects growing investor confidence in the strength of its lead asset, zovegalisib (RLY-2608), a PI3Kα inhibitor, which is advancing into late-stage development with an ongoing phase III breast cancer study (ReDiscover-2). The drug is also being expanded into earlier-line breast cancer settings and non-oncology indications like vascular malformations, with multiple data readouts expected in 2026. The company is also advancing RLY-8161 for Fabry disease, strengthening its genetic disease pipeline. Meanwhile, its FGFR2 inhibitor lirafugratinib (RLY-4008) has been out-licensed to Elevar and already has an NDA filed with the FDA.
This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +23.9%. Revenues are expected to be $15.35 million, up 99.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Relay Therapeutics, the consensus EPS estimate for the quarter has been revised 4.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on RLAY going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Relay Therapeutics belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, electroCore, Inc. (ECOR - Free Report) , closed the last trading session 3% higher at $6.8. Over the past month, ECOR has returned -17.2%.
electroCore's consensus EPS estimate for the upcoming report has changed -10.1% over the past month to -$0.59. Compared to the company's year-ago EPS, this represents a change of -25.5%. electroCore currently boasts a Zacks Rank of #3 (Hold).